PL1809288T3 - Zastosowanie pochodnych 1,4-bis-(3-aminoalkilo)piperazyny do leczenia chorób neurodegeneracyjnych - Google Patents

Zastosowanie pochodnych 1,4-bis-(3-aminoalkilo)piperazyny do leczenia chorób neurodegeneracyjnych

Info

Publication number
PL1809288T3
PL1809288T3 PL05803710T PL05803710T PL1809288T3 PL 1809288 T3 PL1809288 T3 PL 1809288T3 PL 05803710 T PL05803710 T PL 05803710T PL 05803710 T PL05803710 T PL 05803710T PL 1809288 T3 PL1809288 T3 PL 1809288T3
Authority
PL
Poland
Prior art keywords
aminoalkyl
bis
neurodegenerative diseases
piperazine derivatives
treatment
Prior art date
Application number
PL05803710T
Other languages
English (en)
Inventor
Nicolas Sergeant
André Delacourte
Patricia Melnyk
Luc Buee
Original Assignee
Inst Nat Sante Rech Med
Univ Du Droit Et De La Sante Lille Ii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Du Droit Et De La Sante Lille Ii filed Critical Inst Nat Sante Rech Med
Publication of PL1809288T3 publication Critical patent/PL1809288T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C07D219/12—Amino-alkylamino radicals attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL05803710T 2004-11-10 2005-11-08 Zastosowanie pochodnych 1,4-bis-(3-aminoalkilo)piperazyny do leczenia chorób neurodegeneracyjnych PL1809288T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04292674 2004-11-10
PCT/IB2005/053676 WO2006051489A1 (en) 2004-11-10 2005-11-08 Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases
EP05803710A EP1809288B1 (en) 2004-11-10 2005-11-08 Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
PL1809288T3 true PL1809288T3 (pl) 2012-04-30

Family

ID=34931515

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05803710T PL1809288T3 (pl) 2004-11-10 2005-11-08 Zastosowanie pochodnych 1,4-bis-(3-aminoalkilo)piperazyny do leczenia chorób neurodegeneracyjnych

Country Status (9)

Country Link
US (1) US9044478B2 (pl)
EP (1) EP1809288B1 (pl)
JP (1) JP5179190B2 (pl)
AT (1) ATE524181T1 (pl)
CA (1) CA2585983C (pl)
DK (1) DK1809288T3 (pl)
ES (1) ES2373561T3 (pl)
PL (1) PL1809288T3 (pl)
WO (1) WO2006051489A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2774375C (en) 2009-09-17 2018-02-13 Bespoke Bioscience, Llc Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
US8680095B2 (en) 2009-12-16 2014-03-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Heterocycle compounds and uses thereof for the prevention or treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs
WO2011110488A1 (en) * 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft A novel pet imaging agent of amyloid plaques and its precursor
WO2012122405A2 (en) * 2011-03-08 2012-09-13 The Trustees Of Columbia University In The City Of New York Screening assays using stem cells and stem cell-derived neurons from mouse models of alzheimer's disease
CN105008333B (zh) 2012-12-27 2018-02-09 雅尔兹普罗泰特公司 N‑(3‑(4‑(3‑(二异丁基氨基)丙基)哌嗪‑1‑基)丙基)‑1H‑苯并[d]咪唑‑2‑胺的硫酸盐、其制备及其用途
WO2014207241A1 (en) * 2013-06-28 2014-12-31 Alzprotect NEW Na-SUBSTITUTED CARBOLINE COMPOUNDS USABLE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
JP6388456B2 (ja) * 2013-06-28 2018-09-12 アルツプロテクト 神経変性疾患の治療に使用可能なカルボリン化合物
WO2015069844A1 (en) * 2013-11-08 2015-05-14 Perosphere Inc. Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds
HK1245272B (en) 2015-03-16 2019-09-27 Institut National De La Santé Et De La Recherche Médicale (Inserm) Novel 1,4-bis(3-aminopropyl)piperazine derivative and its use
WO2016196393A2 (en) * 2015-05-29 2016-12-08 Presage Biosciences, Inc. Autophagy-inhibiting compounds and uses thereof
WO2020011848A1 (en) 2018-07-11 2020-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Polyamino biaryl compounds and their use
CN116249693A (zh) * 2020-10-01 2023-06-09 雅尔兹普罗泰特公司 N-(3-(4-(3-(二异丁基氨基)丙基)哌嗪-1-基)丙基)-1H-苯并[d]咪唑-2-胺的琥珀酸盐，其制备及其用途
JP7500875B2 (ja) * 2020-10-07 2024-06-17 アルツプロテクト 運動ニューロン疾患及び神経筋接合部障害の処置のためのｎ－（３－（４－（３－（ジイソブチルアミノ）プロピル）ピペラジン－１－イル）プロピル）－１ｈ－ベンゾ［ｄ］イミダゾール－２－アミン硫酸塩及びそれらの溶媒和物の使用
JP7702205B2 (ja) 2021-09-15 2025-07-03 株式会社東芝 新規アミン化合物、酸性ガス吸収剤、酸性ガスの除去方法及び酸性ガス除去
IL313403A (en) * 2021-12-20 2024-08-01 Alzprotect USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[d]IMIDAZOL-2-AMINE SUCCINATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS
ES3075524T3 (en) 2022-03-25 2026-08-05 Alzprotect Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine salts and solvates thereof for the treatment of sensory neuron diseases
EP4601641A1 (en) 2022-10-12 2025-08-20 Institut National de la Santé et de la Recherche Médicale Diphenylpyrazole compounds and their use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2762744A (en) * 1951-08-24 1956-09-11 Lab Bruneau & Cie Piperazine derivatives, production thereof and suppositories comprising the same
US4292321A (en) * 1979-05-24 1981-09-29 Warner-Lambert Company 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof
JP2001500162A (ja) * 1997-06-12 2001-01-09 トランジェーヌ、ソシエテ、アノニム 少なくとも１種の治療上有効な物質、特にポリヌクレオチド、を標的細胞に導入するための新規脂質複合体および遺伝子治療における使用
US6248356B1 (en) * 1997-06-13 2001-06-19 The Picower Institut For Medical Research Immunotherapeutic anti-cancer pharmaceutical compositions
GB9929801D0 (en) * 1999-12-16 2000-02-09 Btg Int Ltd Anti-cancer agents iii
FR2816411B1 (fr) 2000-11-03 2003-07-04 Inst Nat Sante Rech Med Moyens de detection de la transformation pathologique de la proteine app et leurs applications
WO2002096431A1 (en) 2001-05-25 2002-12-05 The Regents Of The University Of California Optically active compounds clearing malformed proteins
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
CA2509406C (en) 2002-12-23 2012-07-03 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
BRPI0515012A (pt) * 2004-08-13 2008-07-01 Genentech Inc substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso

Also Published As

Publication number Publication date
ATE524181T1 (de) 2011-09-15
ES2373561T3 (es) 2012-02-06
CA2585983A1 (en) 2006-05-18
EP1809288B1 (en) 2011-09-14
WO2006051489A1 (en) 2006-05-18
DK1809288T3 (da) 2012-02-06
US9044478B2 (en) 2015-06-02
CA2585983C (en) 2014-03-25
EP1809288A1 (en) 2007-07-25
JP5179190B2 (ja) 2013-04-10
US20090149464A1 (en) 2009-06-11
JP2008519825A (ja) 2008-06-12

Similar Documents

Publication Publication Date Title
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
EP2400847A4 (en) SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOINE COMPOUNDS
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
TW200738242A (en) Dihydropteridinones in the treatment of respiratory diseases
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
DK1809288T3 (da) Anvendelse af 1,4-bis-(3-aminoalkyl)piperazinderivater ved behandling af neurodegenerative sygdomme
TW200630374A (en) Thiazolyldihydroindazoles
CR9182A (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
TW200510427A (en) Novel fused heterocycles and uses thereof
TW200738659A (en) Novel compounds
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
TW200745122A (en) New compounds I
UA89201C2 (ru) Энантиомеры выбранных конденсированных пиримидонов и их применение для лечения и профилактики злокачественного новообразования
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
TW200640911A (en) Novel, long acting betamimetics for the treatment of respiratory diseases
TW200504051A (en) Novel acridine derivatives and their use as medicaments
MY146802A (en) Novel drugs for treating respiratory diseases